Apolipoprotein A-I and Platelet Factor 4 Are Biomarkers for Infliximab Response in Rheumatoid Arthritis

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2008 Jul 31

PMID 18664547

Citations 32

Authors

C Trocme

H Marotte

A Baillet

B Pallot-Prades

J Garin

L Grange

P Miossec

J Tebib

F Berger

M J Nissen

R Juvin

F Morel

P Gaudin

Affiliations

Soon will be listed here.

Abstract

Objectives: The use of biologicals such as infliximab has dramatically improved the treatment of rheumatoid arthritis (RA). However, factors predictive of therapeutic response need to be identified. A proteomic study was performed prior to infliximab therapy to identify a panel of candidate protein biomarkers of RA predictive of treatment response.

Methods: Plasma profiles of 60 patients with RA (28 non-responders (as defined by the American College of Rheumatology 20% improvement criteria (ACR20)) negative and 32 responders (ACR70 positive) to infliximab) were studied by surface enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS) technology on two types of arrays, an anion exchange array (SAX2) and a nickel affinity array (IMAC3-Ni). Biomarker characterisation was carried out using classical biochemical methods (purification by ammonium sulfate precipitation or metal affinity chromatography) and identification by matrix assisted laser desorption/ionisation time-of-flight (MALDI-TOF) MS analysis.

Results: Two distinct protein profiles were observed on both arrays and several proteins were differentially expressed in both patient populations. Five proteins at 3.86, 7.77, 7.97, 8.14 and 74.07 kDa were overexpressed in the non-responder group, whereas one at 28 kDa was increased in the responder population (sensitivity>56%, specificity>77.5%). Moreover, combination of several biomarkers improved the sensitivity and specificity of the detection of patient response to over 97%. The 28 kDa protein was characterised as apolipoprotein A-I and the 7.77 kDa biomarker was identified as platelet factor 4.

Conclusions: Six plasma biomarkers are characterised, enabling the detection of patient response to infliximab with high sensitivity and specificity. Apolipoprotein A-1 was predictive of a good response to infliximab, whereas platelet factor 4 was associated with non-responders.

Citing Articles

Mechanosensing regulates pDC activation in the skin through NRF2 activation.

Chaudhary V, Mishra B, Ah Kioon M, Du Y, Ivashkiv L, Crow M J Exp Med. 2024; 222(3).

PMID: 39670996 PMC: 11639951. DOI: 10.1084/jem.20240852.

Towards Personalized Medicine in Rheumatoid Arthritis.

Sharma S, Bluett J Open Access Rheumatol. 2024; 16:89-114.

PMID: 38779469 PMC: 11110814. DOI: 10.2147/OARRR.S372610.

Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial.

Solomon D, Demler O, Rist P, Santacroce L, Tawakol A, Giles J J Am Heart Assoc. 2024; 13(5):e032095.

PMID: 38416140 PMC: 10944054. DOI: 10.1161/JAHA.123.032095.

The role of CXCR3 and its ligands in cancer.

Wang X, Zhang Y, Wang S, Ni H, Zhao P, Chen G Front Oncol. 2022; 12:1022688.

PMID: 36479091 PMC: 9720144. DOI: 10.3389/fonc.2022.1022688.

Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis.

Jezernik G, Gorenjak M, Potocnik U Biomedicines. 2022; 10(8).

PMID: 36009355 PMC: 9404936. DOI: 10.3390/biomedicines10081808.

References

Lam Y, Mobley J, Evans J, Carmody J, Ho S . Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics. 2005; 5(11):2927-38. DOI: 10.1002/pmic.200401165. View

Molenaar E, Voskuyl A, Dinant H, Bezemer P, Boers M, Dijkmans B . Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 2004; 50(1):36-42. DOI: 10.1002/art.11481. View

Kievit W, Fransen J, Oerlemans A, Kuper H, van der Laar M, De Rooij D . The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007; 66(11):1473-8. PMC: 2111629. DOI: 10.1136/ard.2007.072447. View

Roux C, Saraux A, le Bihan E, Fardellone P, Guggenbuhl P, Fautrel B . Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France. J Rheumatol. 2006; 34(1):117-22. View

Uchida T, Fukawa A, Uchida M, Fujita K, Saito K . Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res. 2003; 1(6):495-9. DOI: 10.1021/pr025531w. View

Morel J, Combe B . How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2004; 19(1):137-46. DOI: 10.1016/j.berh.2004.08.008. View

Ananth L, Prete P, Kashyap M . Apolipoproteins A-I and B and cholesterol in synovial fluid of patients with rheumatoid arthritis. Metabolism. 1993; 42(7):803-6. DOI: 10.1016/0026-0495(93)90050-x. View

Hodgetts A, Levin M, Kroll J, Langford P . Biomarker discovery in infectious diseases using SELDI. Future Microbiol. 2007; 2(1):35-49. DOI: 10.2217/17460913.2.1.35. View

Le Loet X, Berthelot J, Cantagrel A, Combe B, De Bandt M, Fautrel B . Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis. 2005; 65(1):45-50. PMC: 1797976. DOI: 10.1136/ard.2005.035436. View

10.

Slungaard A . Platelet factor 4: a chemokine enigma. Int J Biochem Cell Biol. 2005; 37(6):1162-7. DOI: 10.1016/j.biocel.2004.12.003. View

11.

Burger D, Dayer J . High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation?. Autoimmun Rev. 2003; 1(1-2):111-7. DOI: 10.1016/s1568-9972(01)00018-0. View

12.

Vanhoutte K, Laarakkers C, Marchiori E, Pickkers P, Wetzels J, Willems J . Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools. Nephrol Dial Transplant. 2007; 22(10):2932-43. DOI: 10.1093/ndt/gfm170. View

13.

Zhang Z, Bast Jr R, Yu Y, Li J, Sokoll L, Rai A . Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004; 64(16):5882-90. DOI: 10.1158/0008-5472.CAN-04-0746. View

14.

Erdem H, Pay S, Musabak U, Simsek I, Dinc A, Pekel A . Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis?. Rheumatol Int. 2007; 27(10):969-73. DOI: 10.1007/s00296-007-0317-6. View

15.

de Seny D, Fillet M, Meuwis M, Geurts P, Lutteri L, Ribbens C . Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum. 2005; 52(12):3801-12. DOI: 10.1002/art.21607. View

16.

Marotte H, Pallot-Prades B, Grange L, Tebib J, Gaudin P, Alexandre C . The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis. 2005; 65(3):342-7. PMC: 1798045. DOI: 10.1136/ard.2005.037150. View

17.

Park Y, Lee S, Lee W, Suh C, Lee C, Lee C . Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol. 1999; 26(8):1701-4. View

18.

Seibert V, Wiesner A, Buschmann T, Meuer J . Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol Res Pract. 2004; 200(2):83-94. DOI: 10.1016/j.prp.2004.01.010. View

19.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

20.

Dayer J . The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine. 2002; 69(2):123-32. DOI: 10.1016/s1297-319x(02)00363-9. View